Head-to-head · Cost-Efficiency Index
CoreAge Rx vs Mojoon
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
CoreAge Rx
Anyone optimizing for real value — a transparent flat price you can model for a full year, nationwide, without a bait-and-switch.
Visit CoreAge RxMojoon
Shoppers comfortable reading past a marketing headline to a lower published starting-dose price.
Visit MojoonThe verdict
CoreAge Rx takes it, leading the Cost-Efficiency Index 94 to 53. Best value in the ranking: both molecules at one flat, all-50 price with no teaser step-ups — the lowest true cost of ownership, not the lowest teaser. Mojoon still earns a C — Shoppers comfortable reading past a marketing headline to a lower published starting-dose price.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | CoreAge Rx | Mojoon |
|---|---|---|
| Cost-Efficiency Index | 94/100 | 53/100 |
| Semaglutide / mo | $99/mo | $350/mo (0.25 mg dose, compounded) |
| Tirzepatide / mo | $149/mo | Not disclosed |
| Semaglutide / yr (modeled) | $1,188 | $4,200 |
| Tirzepatide / yr (modeled) | $1,788 | — |
| Coverage | All 50 states | Coverage not published |
| Oral / sublingual | No | Yes |
| Brand-name access | Compounded only | Compounded only |
| Rank here | #1 | #377 |
CoreAge Rx
94/100Where the value is
- Flat all-in monthly price — no intro rate that silently triples after month one, so the modeled annual cost is the real cost
- Both compounded semaglutide and tirzepatide on one account at published prices
- Available in all 50 states — no coverage gamble
The tradeoffs
- Not the rock-bottom sticker price — 30 of the 381 priced semaglutide programs we track list a cheaper figure, though most attach a term or a step-up that CoreAge does not
- No FDA-approved brand-name option (compounded only)
Mojoon
53/100Where the value is
- Publishes an actual price range ($350-$520/treatment) rather than a single vague 'starting at' figure, and explains why the price rises (monthly dose escalation from 0.25 mg to 2.4 mg)
- Claims LegitScript certification, and pharmacy licensure across all 50 states for dispensing even though provider coverage is 48 states
- No long-term contract or hidden fees claimed on the product page
The tradeoffs
- The site's own prominent marketing figure ('$450 per month') is HIGHER than its own disclosed starting-dose floor ($350) — the headline number is not the entry price
- Tirzepatide is listed as an offered treatment in the navigation but its dedicated page carries no pricing at all
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.